ClinicalTrials.gg
CompletedNCT06494761Updated Dec 2, 2025Results posted

A Study in Healthy Men to Test Whether Zongertinib Affects How 3 Other Medicines (Midazolam, Omeprazole, and Repaglinide) Are Taken up and Processed by the Body

A Phase 1 interventional study of zongertinib and midazolam in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-02.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The main objective of this trial is to assess the effect of multiple oral doses of zongertinib on the pharmacokinetics of midazolam, omeprazole and repaglinide.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead (ECG), and clinical laboratory tests
  • Age of 18 to 55 years (inclusive)
  • (BMI) of 18.5 to 29.9 kg/m2 (inclusive)
  • Signed and dated written

Exclusion criteria

Exclusion Criteria:

  • Any finding in the medical examination (including BP, PR or ) deviating from normal and assessed as by the investigator
  • Repeated measurement of systolic blood pressure outside the range of 90 to 140 millimetre(s) of mercury (mmHg), diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 45 to 90 beats per minute (bpm)
  • Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
  • Any evidence of a concomitant disease assessed as clinically relevant by the investigator Further exclusion criteria apply.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Repaglinide+Midazolam+Omeprazole (Reference)/ Zongertinib+Repaglinide+Midazolam+Omeprazole (Test)

    Reference (Repaglinide + Midazolam + Omeprazole) In the reference treatment period (Period 1), participants received 0.5 mg repaglinide tablet (Day 1, after ≥10 h fast; Reference Treatment 1). On Day 2, they received 1 mg midazolam (0.5 mL oral solution) with 20 mg omeprazole tablet under the same fasting conditions (Reference Treatment 2). Test (Zongertinib + Repaglinide + Midazolam + Omeprazole) In the test treatment period (Period 2), participants received multiple once-daily doses of 120 mg zongertinib from Day 1 to Day 15. A single 0.5 mg repaglinide tablet was co-administered on Day 1 (Test Treatment 1) and Day 14 (Test Treatment 3), and a single dose of the probe drug cocktail containing 1 mg midazolam (0.5 mL oral solution) and 20 mg omeprazole tablet was co-administered on Day 2 (Test Treatment 2) and Day 15 (Test Treatment 4).

    Drug: zongertinib · Drug: midazolam · Drug: omeprazole · Drug: repaglinide

Interventions

  • Participants received 120 mg Zongertinib daily as two 60 mg tablets.

    Also known as: BI 1810631

  • Participants received 1 mg Midazolam as 0.5 mL oral solution.

  • Participants received 20 mg Omeprazole.

  • Participants received a 0.5 mg Repaglinide.

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve of Repaglinide in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC₀-∞)

    The area under the concentration-time curve of repaglinide in plasma over the time interval from 0 extrapolated to infinity ((AUC0-∞) is reported. Period 1 (Day 1): Up to 3 hours pre-dose and at 15, 30, and 45 minutes, and 1, 1.5, 2, 2.5, 3-, 4-, 6-, and 24-hours post-dose. Period 2 (Day 1): Up to 3 hours pre-dose and at 15, 30, and 45 minutes, and 1, 1.5, 2, 2.5, 3-, 4-, 6-, and 24-hours post-dose. Period 2 (Day 14): ≤15 min pre-dose and at 15, 30, 45 min; 1, 1.5, 2, 2.5, 3-, 4-,6-, and 24-hours post-dose.

    Time frame: Samples were collected on Day 1 (Period 1), Day 1 (Period 2), and Day 14 (Period 2). See endpoint description for the full sampling schedule

  2. Area Under the Concentration-time Curve of Midazolam in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC₀-∞)

    The area under the concentration-time curve of midazolam in plasma over the time interval from 0 extrapolated to infinity ((AUC0-∞) is reported. Period 1 (Day 2): 15 min pre-dose and at 15, 30, 45 min; 1, 1.5, 2, 4, 6, 8, 10, 12 hours post-dose. Period 2 (Day 2): 15 min pre-dose and at 15, 30, 45 min; 1, 1.5, 2, 4, 6, 8, 10, 12 h post-dose. Period 2 (Day 15): 15 min pre-dose, and at 15, 30, 45 min; 1, 1.5, 2, 4, 6, 8, 10, 11, 12 hours post-dose.

    Time frame: Samples were collected on Day 2 (Period 1), Day 2 (Period 2), and Day 15 (Period 2). See endpoint description for the full sampling schedule

  3. Area Under the Concentration-time Curve of Omeprazole in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC₀-∞)

    The area under the concentration-time curve of omeprazole in plasma over the time interval from 0 extrapolated to infinity ((AUC0-∞) is reported. Period 1 (Day 2): 15 min pre-dose and at 15, 30, 45 min; 1, 1.5, 2, 4, 6, 8, 10, 12 hours post-dose. Period 2 (Day 2): 15 min pre-dose and at 15, 30, 45 min; 1, 1.5, 2, 4, 6, 8, 10, 12 h post-dose. Period 2 (Day 15): 15 min pre-dose, and at 15, 30, 45 min; 1, 1.5, 2, 4, 6, 8, 10, 11, 12 hours post-dose.

    Time frame: Samples were collected on Day 2 (Period 1), Day 2 (Period 2), and Day 15 (Period 2). See endpoint description for the full sampling schedule

  4. Maximum Measured Concentration of Repaglinide in Plasma (Cmax)

    The maximum measured concentration of repaglinide in plasma is reported. Period 1 (Day 1): Up to 3 hours pre-dose and at 15, 30, and 45 minutes, and 1, 1.5, 2, 2.5, 3-, 4-, 6-, and 24-hours post-dose. Period 2 (Day 1): Up to 3 hours pre-dose and at 15, 30, and 45 minutes, and 1, 1.5, 2, 2.5, 3-, 4-, 6-, and 24-hours post-dose. Period 2 (Day 14): ≤15 min pre-dose and at 15, 30, 45 min; 1, 1.5, 2, 2.5, 3-, 4-,6-, and 24-hours post-dose.

    Time frame: Samples were collected on Day 1 (Period 1), Day 1 (Period 2), and Day 14 (Period 2). See endpoint description for the full sampling schedule

  5. Maximum Measured Concentration of Midazolam in Plasma (Cmax)

    The maximum measured concentration of midazolam in plasma is reported. Period 1 (Day 2): 15 min pre-dose and at 15, 30, 45 min; 1, 1.5, 2, 4, 6, 8, 10, 12 hours post-dose. Period 2 (Day 2): 15 min pre-dose and at 15, 30, 45 min; 1, 1.5, 2, 4, 6, 8, 10, 12 h post-dose. Period 2 (Day 15): 15 min pre-dose, and at 15, 30, 45 min; 1, 1.5, 2, 4, 6, 8, 10, 11, 12 hours post-dose.

    Time frame: Samples were collected on Day 2 (Period 1), Day 2 (Period 2), and Day 15 (Period 2). See endpoint description for the full sampling schedule

  6. Maximum Measured Concentration of Omeprazole in Plasma (Cmax)

    The maximum measured concentration of omeprazole in plasma is reported. Period 1 (Day 2): 15 min pre-dose and at 15, 30, 45 min; 1, 1.5, 2, 4, 6, 8, 10, 12 hours post-dose. Period 2 (Day 2): 15 min pre-dose and at 15, 30, 45 min; 1, 1.5, 2, 4, 6, 8, 10, 12 h post-dose. Period 2 (Day 15): 15 min pre-dose, and at 15, 30, 45 min; 1, 1.5, 2, 4, 6, 8, 10, 11, 12 hours post-dose.

    Time frame: Samples were collected on Day 2 (Period 1), Day 2 (Period 2), and Day 15 (Period 2). See endpoint description for the full sampling schedule

Secondary outcomes

  1. Area Under the Concentration-time Curve of Repaglinide in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

    The area under the concentration-time curve of repaglinide in plasma over the time interval from 0 to the last quantifiable data poin is reported. Period 1 (Day 1): Up to 3 hours pre-dose and at 15, 30, and 45 minutes, and 1, 1.5, 2, 2.5, 3-, 4-, 6-, and 24-hours post-dose. Period 2 (Day 1): Up to 3 hours pre-dose and at 15, 30, and 45 minutes, and 1, 1.5, 2, 2.5, 3-, 4-, 6-, and 24-hours post-dose. Period 2 (Day 14): ≤15 min pre-dose and at 15, 30, 45 min; 1, 1.5, 2, 2.5, 3-, 4-,6-, and 24-hours post-dose.

    Time frame: Samples were collected on Day 1 (Period 1), Day 1 (Period 2), and Day 14 (Period 2). See endpoint description for the full sampling schedule

  2. Area Under the Concentration-time Curve of Midazolam in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

    The area under the concentration-time curve of midazolam in plasma over the time interval from 0 to the last quantifiable data point is reported. Period 1 (Day 2): 15 min pre-dose and at 15, 30, 45 min; 1, 1.5, 2, 4, 6, 8, 10, 12 hours post-dose. Period 2 (Day 2): 15 min pre-dose and at 15, 30, 45 min; 1, 1.5, 2, 4, 6, 8, 10, 12 h post-dose. Period 2 (Day 15): 15 min pre-dose, and at 15, 30, 45 min; 1, 1.5, 2, 4, 6, 8, 10, 11, 12 hours post-dose.

    Time frame: Samples were collected on Day 2 (Period 1), Day 2 (Period 2), and Day 15 (Period 2). See endpoint description for the full sampling schedule

  3. Area Under the Concentration-time Curve of Omeprazole in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

    The area under the concentration-time curve of omeprazole in plasma over the time interval from 0 to the last quantifiable data point is reported. Period 1 (Day 2): 15 min pre-dose and at 15, 30, 45 min; 1, 1.5, 2, 4, 6, 8, 10, 12 hours post-dose. Period 2 (Day 2): 15 min pre-dose and at 15, 30, 45 min; 1, 1.5, 2, 4, 6, 8, 10, 12 h post-dose. Period 2 (Day 15): 15 min pre-dose, and at 15, 30, 45 min; 1, 1.5, 2, 4, 6, 8, 10, 11, 12 hours post-dose.

    Time frame: Samples were collected on Day 2 (Period 1), Day 2 (Period 2), and Day 15 (Period 2). See endpoint description for the full sampling schedule

07

Results

Posted Dec 2, 2025

Participant flow

This non-randomized, open-label, two-period, fixed-sequence trial evaluated the effect of multiple oral doses of zongertinib on the single-dose pharmacokinetics of midazolam, omeprazole, and repaglinide in healthy male subjects to assess potential drug-drug interactions.

Period 1 (Reference Period) (3 days)
Participant flow — Period 1 (Reference Period) (3 days)
MilestoneRepaglinide+Midazolam+Omeprazole (Reference)/ Zongertinib+Repaglinide+Midazolam+Omeprazole (Test)
Started16
Completed16
Not completed0
Washout (3 days)
Participant flow — Washout (3 days)
MilestoneRepaglinide+Midazolam+Omeprazole (Reference)/ Zongertinib+Repaglinide+Midazolam+Omeprazole (Test)
Started16
Completed16
Not completed0
Period 2: (Test Period) (15 days)
Participant flow — Period 2: (Test Period) (15 days)
MilestoneRepaglinide+Midazolam+Omeprazole (Reference)/ Zongertinib+Repaglinide+Midazolam+Omeprazole (Test)
Started16
Completed14
Not completed2
Withdrew: Adverse event1
Withdrew: Physician decision1

Outcome measures

PrimaryArea Under the Concentration-time Curve of Repaglinide in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC₀-∞)

The area under the concentration-time curve of repaglinide in plasma over the time interval from 0 extrapolated to infinity ((AUC0-∞) is reported. Period 1 (Day 1): Up to 3 hours pre-dose and at 15, 30, and 45 minutes, and 1, 1.5, 2, 2.5, 3-, 4-, 6-, and 24-hours post-dose. Period 2 (Day 1): Up to 3 hours pre-dose and at 15, 30, and 45 minutes, and 1, 1.5, 2, 2.5, 3-, 4-, 6-, and 24-hours post-dose. Period 2 (Day 14): ≤15 min pre-dose and at 15, 30, 45 min; 1, 1.5, 2, 2.5, 3-, 4-,6-, and 24-hours post-dose.

Time frame:
Samples were collected on Day 1 (Period 1), Day 1 (Period 2), and Day 14 (Period 2). See endpoint description for the full sampling schedule
Reported as:
Geometric mean · Hours × picomoles per liter (h*pmol/L)
Area Under the Concentration-time Curve of Repaglinide in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC₀-∞)
Hours × picomoles per liter (h*pmol/L)Repaglinide Alone (Reference Treatment 1)Repaglinide with a single dose of zongertinib (Test Treatment 1)Repaglinide after multiple doses of zongertinib (Test Treatment 3)
Area Under the Concentration-time Curve of Repaglinide in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC₀-∞)28100 ± 58.031200 ± 49.237300 ± 48.7
Statistical analysis
  • Repaglinide Alone (Reference Treatment 1) vs Repaglinide with a single dose of zongertinib (Test Treatment 1) · Ratios of adjusted geometric means [%]: 110.98 · 90% CI 96.90 to 127.10Ratio calculated as test/reference\*100. Intra-individual Geometric coefficient of variation \[%\] = 22.1
  • Repaglinide Alone (Reference Treatment 1) vs Repaglinide after multiple doses of zongertinib (Test Treatment 3) · Ratios of adjusted geometric means [%]: 130.10 · 90% CI 110.35 to 153.39Ratio calculated as test/reference\*100. Intra-individual Geometric coefficient of variation \[%\] = 25.2
PrimaryArea Under the Concentration-time Curve of Midazolam in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC₀-∞)

The area under the concentration-time curve of midazolam in plasma over the time interval from 0 extrapolated to infinity ((AUC0-∞) is reported. Period 1 (Day 2): 15 min pre-dose and at 15, 30, 45 min; 1, 1.5, 2, 4, 6, 8, 10, 12 hours post-dose. Period 2 (Day 2): 15 min pre-dose and at 15, 30, 45 min; 1, 1.5, 2, 4, 6, 8, 10, 12 h post-dose. Period 2 (Day 15): 15 min pre-dose, and at 15, 30, 45 min; 1, 1.5, 2, 4, 6, 8, 10, 11, 12 hours post-dose.

Time frame:
Samples were collected on Day 2 (Period 1), Day 2 (Period 2), and Day 15 (Period 2). See endpoint description for the full sampling schedule
Reported as:
Geometric mean · Hours × picomoles per liter (h*pmol/L)
Area Under the Concentration-time Curve of Midazolam in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC₀-∞)
Hours × picomoles per liter (h*pmol/L)Midazolam + Omeprazole (Reference Treatment 2)Midazolam + Omeprazole with a single dose of zongertinib (Test Treatment 2)Midazolam + Omeprazole after multiple doses of zongertinib (Test Treatment 4)
Area Under the Concentration-time Curve of Midazolam in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC₀-∞)41400 ± 33.544200 ± 37.343400 ± 27.9
Statistical analysis
  • Midazolam + Omeprazole (Reference Treatment 2) vs Midazolam + Omeprazole with a single dose of zongertinib (Test Treatment 2) · Ratios of adjusted geometric means [%]: 107.80 · 90% CI 98.57 to 117.90Ratio calculated as test/reference\*100. Intra-individual Geometric coefficient of variation \[%\] = 13.5
  • Midazolam + Omeprazole (Reference Treatment 2) vs Midazolam + Omeprazole after multiple doses of zongertinib (Test Treatment 4) · Ratios of adjusted geometric means [%]: 105.62 · 90% CI 95.41 to 116.93Ratio calculated as test/reference\*100. Intra-individual Geometric coefficient of variation \[%\] = 15.4
PrimaryArea Under the Concentration-time Curve of Omeprazole in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC₀-∞)

The area under the concentration-time curve of omeprazole in plasma over the time interval from 0 extrapolated to infinity ((AUC0-∞) is reported. Period 1 (Day 2): 15 min pre-dose and at 15, 30, 45 min; 1, 1.5, 2, 4, 6, 8, 10, 12 hours post-dose. Period 2 (Day 2): 15 min pre-dose and at 15, 30, 45 min; 1, 1.5, 2, 4, 6, 8, 10, 12 h post-dose. Period 2 (Day 15): 15 min pre-dose, and at 15, 30, 45 min; 1, 1.5, 2, 4, 6, 8, 10, 11, 12 hours post-dose.

Time frame:
Samples were collected on Day 2 (Period 1), Day 2 (Period 2), and Day 15 (Period 2). See endpoint description for the full sampling schedule
Reported as:
Geometric mean · hour * nanogram per milliliter (h*ng/mL)
Area Under the Concentration-time Curve of Omeprazole in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC₀-∞)
hour * nanogram per milliliter (h*ng/mL)Midazolam + Omeprazole (Reference Treatment 2)Midazolam + Omeprazole after a single dose of zongertinib (Test Treatments 2)Midazolam + Omeprazole after multiple doses of zongertinib (Test Treatment 4)
Area Under the Concentration-time Curve of Omeprazole in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC₀-∞)378 ± 69.7359 ± 66.9296 ± 60.2
Statistical analysis
  • Midazolam + Omeprazole (Reference Treatment 2) vs Midazolam + Omeprazole after a single dose of zongertinib (Test Treatments 2) · Ratios of adjusted geometric means [%]: 96.55 · 90% CI 75.96 to 122.72Ratio calculated as test/reference\*100. Intra-individual Geometric coefficient of variation \[%\] = 24.5
  • Midazolam + Omeprazole (Reference Treatment 2) vs Midazolam + Omeprazole after multiple doses of zongertinib (Test Treatment 4) · Ratios of adjusted geometric means [%]: 89.75 · 90% CI 61.86 to 130.20Ratio calculated as test/reference\*100. Intra-individual Geometric coefficient of variation \[%\] = 39.6
PrimaryMaximum Measured Concentration of Repaglinide in Plasma (Cmax)

The maximum measured concentration of repaglinide in plasma is reported. Period 1 (Day 1): Up to 3 hours pre-dose and at 15, 30, and 45 minutes, and 1, 1.5, 2, 2.5, 3-, 4-, 6-, and 24-hours post-dose. Period 2 (Day 1): Up to 3 hours pre-dose and at 15, 30, and 45 minutes, and 1, 1.5, 2, 2.5, 3-, 4-, 6-, and 24-hours post-dose. Period 2 (Day 14): ≤15 min pre-dose and at 15, 30, 45 min; 1, 1.5, 2, 2.5, 3-, 4-,6-, and 24-hours post-dose.

Time frame:
Samples were collected on Day 1 (Period 1), Day 1 (Period 2), and Day 14 (Period 2). See endpoint description for the full sampling schedule
Reported as:
Geometric mean · Picomoles per liter (pmol/L)
Maximum Measured Concentration of Repaglinide in Plasma (Cmax)
Picomoles per liter (pmol/L)Repaglinide Alone (Reference Treatment 1)Repaglinide with a single dose of zongertinib (Test Treatments 1)Repaglinide after multiple doses of zongertinib (Test Treatment 3)
Maximum Measured Concentration of Repaglinide in Plasma (Cmax)20200 ± 52.623600 ± 40.929700 ± 36.8
Statistical analysis
  • Repaglinide Alone (Reference Treatment 1) vs Repaglinide with a single dose of zongertinib (Test Treatments 1) · Ratios of adjusted geometric means [%]: 117.07 · 90% CI 105.56 to 129.84Ratio calculated as test/reference\*100. Intra-individual Geometric coefficient of variation \[%\] = 16.8
  • Repaglinide Alone (Reference Treatment 1) vs Repaglinide after multiple doses of zongertinib (Test Treatment 3) · Ratios of adjusted geometric means [%]: 144.36 · 90% CI 123.53 to 168.71Ratio calculated as test/reference\*100. Intra-individual Geometric coefficient of variation \[%\] = 23.9
PrimaryMaximum Measured Concentration of Midazolam in Plasma (Cmax)

The maximum measured concentration of midazolam in plasma is reported. Period 1 (Day 2): 15 min pre-dose and at 15, 30, 45 min; 1, 1.5, 2, 4, 6, 8, 10, 12 hours post-dose. Period 2 (Day 2): 15 min pre-dose and at 15, 30, 45 min; 1, 1.5, 2, 4, 6, 8, 10, 12 h post-dose. Period 2 (Day 15): 15 min pre-dose, and at 15, 30, 45 min; 1, 1.5, 2, 4, 6, 8, 10, 11, 12 hours post-dose.

Time frame:
Samples were collected on Day 2 (Period 1), Day 2 (Period 2), and Day 15 (Period 2). See endpoint description for the full sampling schedule
Reported as:
Geometric mean · Picomoles per liter (pmol/L)
Maximum Measured Concentration of Midazolam in Plasma (Cmax)
Picomoles per liter (pmol/L)Midazolam + Omeprazole (Reference Treatment 2)Midazolam + Omeprazole after a single dose of zongertinib (Test Treatments 2)Midazolam + Omeprazole after multiple doses of zongertinib (Test Treatment 4)
Maximum Measured Concentration of Midazolam in Plasma (Cmax)17700 ± 25.819700 ± 33.020800 ± 26.0
Statistical analysis
  • Midazolam + Omeprazole (Reference Treatment 2) vs Midazolam + Omeprazole after a single dose of zongertinib (Test Treatments 2) · Ratios of adjusted geometric means [%]: 110.74 · 90% CI 100.92 to 121.52Ratio calculated as test/reference\*100. Intra-individual Geometric coefficient of variation \[%\] = 14.1
  • Midazolam + Omeprazole (Reference Treatment 2) vs Midazolam + Omeprazole after multiple doses of zongertinib (Test Treatment 4) · Ratios of adjusted geometric means [%]: 117.19 · 90% CI 108.30 to 126.81Ratio calculated as test/reference\*100. Intra-individual Geometric coefficient of variation \[%\] = 11.9
PrimaryMaximum Measured Concentration of Omeprazole in Plasma (Cmax)

The maximum measured concentration of omeprazole in plasma is reported. Period 1 (Day 2): 15 min pre-dose and at 15, 30, 45 min; 1, 1.5, 2, 4, 6, 8, 10, 12 hours post-dose. Period 2 (Day 2): 15 min pre-dose and at 15, 30, 45 min; 1, 1.5, 2, 4, 6, 8, 10, 12 h post-dose. Period 2 (Day 15): 15 min pre-dose, and at 15, 30, 45 min; 1, 1.5, 2, 4, 6, 8, 10, 11, 12 hours post-dose.

Time frame:
Samples were collected on Day 2 (Period 1), Day 2 (Period 2), and Day 15 (Period 2). See endpoint description for the full sampling schedule
Reported as:
Geometric mean · Nanograms per milliliter (ng/mL)
Maximum Measured Concentration of Omeprazole in Plasma (Cmax)
Nanograms per milliliter (ng/mL)Midazolam + Omeprazole (Reference Treatment 2)Midazolam + Omeprazole after a single dose of zongertinib (Test Treatments 2)Midazolam + Omeprazole after multiple doses of zongertinib (Test Treatment 4)
Maximum Measured Concentration of Omeprazole in Plasma (Cmax)165 ± 91.7131 ± 78.3101 ± 79.3
Statistical analysis
  • Midazolam + Omeprazole (Reference Treatment 2) vs Midazolam + Omeprazole after a single dose of zongertinib (Test Treatments 2) · Ratios of adjusted geometric means [%]: 79.39 · 90% CI 49.90 to 126.30Ratio calculated as test/reference\*100. Intra-individual Geometric coefficient of variation \[%\] = 77.6
  • Midazolam + Omeprazole (Reference Treatment 2) vs Midazolam + Omeprazole after multiple doses of zongertinib (Test Treatment 4) · Ratios of adjusted geometric means [%]: 62.07 · 90% CI 44.69 to 86.20Ratio calculated as test/reference\*100. Intra-individual Geometric coefficient of variation \[%\] = 49.1
SecondaryArea Under the Concentration-time Curve of Repaglinide in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

The area under the concentration-time curve of repaglinide in plasma over the time interval from 0 to the last quantifiable data poin is reported. Period 1 (Day 1): Up to 3 hours pre-dose and at 15, 30, and 45 minutes, and 1, 1.5, 2, 2.5, 3-, 4-, 6-, and 24-hours post-dose. Period 2 (Day 1): Up to 3 hours pre-dose and at 15, 30, and 45 minutes, and 1, 1.5, 2, 2.5, 3-, 4-, 6-, and 24-hours post-dose. Period 2 (Day 14): ≤15 min pre-dose and at 15, 30, 45 min; 1, 1.5, 2, 2.5, 3-, 4-,6-, and 24-hours post-dose.

Time frame:
Samples were collected on Day 1 (Period 1), Day 1 (Period 2), and Day 14 (Period 2). See endpoint description for the full sampling schedule
Reported as:
Geometric mean · Hours × picomoles per liter (h*pmol/L)
Area Under the Concentration-time Curve of Repaglinide in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
Hours × picomoles per liter (h*pmol/L)Repaglinide Alone (Reference Treatment 1)Repaglinide with a single dose of zongertinib (Test Treatments 1)Repaglinide after multiple doses of zongertinib (Test Treatment 3)
Area Under the Concentration-time Curve of Repaglinide in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)27700 ± 58.330700 ± 50.536700 ± 48.7
Statistical analysis
  • Repaglinide Alone (Reference Treatment 1) vs Repaglinide with a single dose of zongertinib (Test Treatments 1) · Ratios of adjusted geometric means [%]: 110.86 · 90% CI 96.58 to 127.24Ratio calculated as test/reference\*100. Intra-individual Geometric coefficient of variation \[%\] = 22.5
  • Repaglinide Alone (Reference Treatment 1) vs Repaglinide after multiple doses of zongertinib (Test Treatment 3) · Ratios of adjusted geometric means [%]: 129.80 · 90% CI 109.70 to 153.59Ratio calculated as test/reference\*100. Intra-individual Geometric coefficient of variation \[%\] = 25.8
SecondaryArea Under the Concentration-time Curve of Midazolam in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

The area under the concentration-time curve of midazolam in plasma over the time interval from 0 to the last quantifiable data point is reported. Period 1 (Day 2): 15 min pre-dose and at 15, 30, 45 min; 1, 1.5, 2, 4, 6, 8, 10, 12 hours post-dose. Period 2 (Day 2): 15 min pre-dose and at 15, 30, 45 min; 1, 1.5, 2, 4, 6, 8, 10, 12 h post-dose. Period 2 (Day 15): 15 min pre-dose, and at 15, 30, 45 min; 1, 1.5, 2, 4, 6, 8, 10, 11, 12 hours post-dose.

Time frame:
Samples were collected on Day 2 (Period 1), Day 2 (Period 2), and Day 15 (Period 2). See endpoint description for the full sampling schedule
Reported as:
Geometric mean · Hours × picomoles per liter (h*pmol/L)
Area Under the Concentration-time Curve of Midazolam in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
Hours × picomoles per liter (h*pmol/L)Midazolam + Omeprazole (Reference Treatment 2)Midazolam + Omeprazole after a single dose of zongertinib (Test Treatments 2)Midazolam + Omeprazole after multiple doses of zongertinib (Test Treatment 4)
Area Under the Concentration-time Curve of Midazolam in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)39600 ± 33.642700 ± 38.141700 ± 27.7
Statistical analysis
  • Midazolam + Omeprazole (Reference Treatment 2) vs Midazolam + Omeprazole after a single dose of zongertinib (Test Treatments 2) · Ratios of adjusted geometric means [%]: 108.61 · 90% CI 98.79 to 119.41Ratio calculated as test/reference\*100. Intra-individual Geometric coefficient of variation \[%\] = 14.3
  • Midazolam + Omeprazole (Reference Treatment 2) vs Midazolam + Omeprazole after multiple doses of zongertinib (Test Treatment 4) · Ratios of adjusted geometric means [%]: 106.03 · 90% CI 95.49 to 117.73Ratio calculated as test/reference\*100. Intra-individual Geometric coefficient of variation \[%\] = 15.9
SecondaryArea Under the Concentration-time Curve of Omeprazole in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

The area under the concentration-time curve of omeprazole in plasma over the time interval from 0 to the last quantifiable data point is reported. Period 1 (Day 2): 15 min pre-dose and at 15, 30, 45 min; 1, 1.5, 2, 4, 6, 8, 10, 12 hours post-dose. Period 2 (Day 2): 15 min pre-dose and at 15, 30, 45 min; 1, 1.5, 2, 4, 6, 8, 10, 12 h post-dose. Period 2 (Day 15): 15 min pre-dose, and at 15, 30, 45 min; 1, 1.5, 2, 4, 6, 8, 10, 11, 12 hours post-dose.

Time frame:
Samples were collected on Day 2 (Period 1), Day 2 (Period 2), and Day 15 (Period 2). See endpoint description for the full sampling schedule
Reported as:
Geometric mean · h*ng/mL
Area Under the Concentration-time Curve of Omeprazole in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
h*ng/mLMidazolam + Omeprazole (Reference Treatment 2)Midazolam + Omeprazole after a single dose of zongertinib (Test Treatments 2)Midazolam + Omeprazole after multiple doses of zongertinib (Test Treatment 4)
Area Under the Concentration-time Curve of Omeprazole in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)287 ± 78.3304 ± 72.8267 ± 61.8
Statistical analysis
  • Midazolam + Omeprazole (Reference Treatment 2) vs Midazolam + Omeprazole after a single dose of zongertinib (Test Treatments 2) · Ratios of adjusted geometric means [%]: 108.13 · 90% CI 79.90 to 146.35Ratio calculated as test/reference\*100. Intra-individual Geometric coefficient of variation \[%\] = 44.9
  • Midazolam + Omeprazole (Reference Treatment 2) vs Midazolam + Omeprazole after multiple doses of zongertinib (Test Treatment 4) · Ratios of adjusted geometric means [%]: 97.81 · 90% CI 75.01 to 127.53Ratio calculated as test/reference\*100. Intra-individual Geometric coefficient of variation \[%\] = 38.5

Adverse events

Collected over AE collection timeframe: Repa (R1) & Zonger+Repa (T1, T3): up to 24h; Mida+Ome (R2) & Zonger+Mida+Ome (T2, T4): up to 48h; Zonger: up to 14d post-dose. All-cause mortality: Up to 50 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Repaglinide (Reference Treatment 1)0/16 (0%)0/16 (0%)2/16 (12.5%)
Midazolam + Omeprazole (Reference Treatment 2)0/16 (0%)0/16 (0%)2/16 (12.5%)
Zongertinib +Repaglinide (Test Treatment 1)0/16 (0%)0/16 (0%)4/16 (25%)
Zongertinib +Midazolam +Omeprazole (Test Treatment 2)0/14 (0%)0/14 (0%)4/14 (28.6%)
Zongertinib0/14 (0%)0/14 (0%)9/14 (64.3%)
Zongertinib +Repaglinide (Test Treatment 3)0/14 (0%)0/14 (0%)2/14 (14.3%)
Zongertinib + Midazolam + Omeprazole (Test Treatment 4)0/14 (0%)0/14 (0%)4/14 (28.6%)
Most frequent other events
Showing 10 of 22
Most frequent other events
EventRepaglinide (Reference Treatment 1)Midazolam + Omeprazole (Reference Treatment 2)Zongertinib +Repaglinide (Test Treatment 1)Zongertinib +Midazolam +Omeprazole (Test Treatment 2)ZongertinibZongertinib +Repaglinide (Test Treatment 3)Zongertinib + Midazolam + Omeprazole (Test Treatment 4)
HeadacheNervous system disorders1/161/162/161/143/140/140/14
DiarrhoeaGastrointestinal disorders0/160/160/161/142/141/140/14
Gastrooesophageal reflux diseaseGastrointestinal disorders0/160/160/160/142/140/140/14
Dermatitis acneiformSkin and subcutaneous tissue disorders0/160/160/160/142/140/141/14
Dry skinSkin and subcutaneous tissue disorders0/160/160/160/142/140/140/14
NauseaGastrointestinal disorders0/160/160/160/141/140/140/14
StomatitisGastrointestinal disorders0/160/160/160/141/140/140/14
MalaiseGeneral disorders0/160/160/160/141/140/140/14
RhinitisInfections and infestations0/160/160/161/140/140/140/14
Hand fractureInjury, poisoning and procedural complications0/160/160/160/141/140/140/14

Baseline characteristics

Treated set (TS): The treated set includes all subjects who were treated with at least one dose of trial drug.

Age, Continuous
Age, Continuous(Years)Repaglinide+Midazolam+Omeprazole (Reference)/ Zongertinib+Repaglinide+Midazolam+Omeprazole (Test)
Mean35.6 ± 12.1
Sex: Female, Male
Sex: Female, Male(Participants)Repaglinide+Midazolam+Omeprazole (Reference)/ Zongertinib+Repaglinide+Midazolam+Omeprazole (Test)
Female0
Male16
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Repaglinide+Midazolam+Omeprazole (Reference)/ Zongertinib+Repaglinide+Midazolam+Omeprazole (Test)
Hispanic or Latino0
Not Hispanic or Latino16
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Repaglinide+Midazolam+Omeprazole (Reference)/ Zongertinib+Repaglinide+Midazolam+Omeprazole (Test)
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White16
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • Humanpharmakologisches Zentrum Biberach
    Biberach, 88397, Germany
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2024 to primary completion in Oct 2024, 2 months.

Results were first posted in Dec 2025, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2024
First posted
Jul 10, 2024
StartActual
Jul 30, 2024
Primary completionActual
Oct 16, 2024
CompletionActual
Oct 16, 2024
Results first posted
Dec 2, 2025
Last update
Dec 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06494761
Responsible party
Sponsor
First posted
Jul 10, 2024
Start date
Jul 30, 2024
Primary completion
Oct 16, 2024
Completion
Oct 16, 2024
Results posted
Dec 2, 2025
Last update
Dec 2, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zongertinib

Start the discussion